Literature DB >> 17372153

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Tina Vilsbøll1, Milan Zdravkovic, Tu Le-Thi, Thure Krarup, Ole Schmitz, Jean-Pierre Courrèges, Robert Verhoeven, Ingrid Bugánová, Sten Madsbad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17372153     DOI： 10.2337/dc06-2593

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  113 in total

1.  An analysis of dosage volume for halfway doses in the Victoza Pen.

Authors:  Lisa Kroon
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

Review 2.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

3.  Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

Authors:  Mansur Shomali
Journal:  Clin Diabetes       Date:  2014-01

Review 4.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

Review 5.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

6.  Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Authors:  Leonor Corsino; Mary Elizabeth Cox; Jennifer Rowel; Jennifer B Green
Journal:  Clin Med Ther       Date:  2009-08-27

Review 7.  Incretin-based therapies for type 2 diabetes mellitus.

Authors:  Julie A Lovshin; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

Authors:  Lisbeth V Jacobsen; Charlotte Hindsberger; Richard Robson; Milan Zdravkovic
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 10.  Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Authors:  Baptist Gallwitz
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.